SG11201811434RA - Antimalarial compositions and uses thereof - Google Patents

Antimalarial compositions and uses thereof

Info

Publication number
SG11201811434RA
SG11201811434RA SG11201811434RA SG11201811434RA SG11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA
Authority
SG
Singapore
Prior art keywords
california
international
san diego
road
jolla
Prior art date
Application number
SG11201811434RA
Other languages
English (en)
Inventor
Wil Joseph Andahazy
Arnab K Chatterjee
Case W Mcnamara
Federico C Beasley
Anders Mikal Eliasen
Hank Michael James Petrassi
Jason T Roland
Timothy Wells
Olga Vladimirovna Zatolochnaya
Fei Zhou
Peter G Schultz
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG11201811434RA publication Critical patent/SG11201811434RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62Halogen-containing esters
    • C07C69/65Halogen-containing esters of unsaturated acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00Quinones
    • C07C50/26Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201811434RA 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof SG11201811434RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352455P 2016-06-20 2016-06-20
PCT/US2017/038173 WO2017222996A1 (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11201811434RA true SG11201811434RA (en) 2019-01-30

Family

ID=60784061

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201811434RA SG11201811434RA (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof
SG10202112759SA SG10202112759SA (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202112759SA SG10202112759SA (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Country Status (12)

Country Link
US (3) US10947176B2 (https=)
EP (1) EP3471711A4 (https=)
JP (1) JP2019523779A (https=)
KR (1) KR20190020774A (https=)
CN (2) CN109715147A (https=)
AU (1) AU2017281426B2 (https=)
BR (1) BR112018076619A2 (https=)
CA (1) CA3028392A1 (https=)
EA (1) EA201990064A1 (https=)
MA (1) MA45411A (https=)
SG (2) SG11201811434RA (https=)
WO (1) WO2017222996A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201990064A1 (ru) * 2016-06-20 2019-05-31 Дзе Скриппс Рисерч Инститьют Противомалярийные композиции и варианты их применения
WO2020051130A1 (en) * 2018-09-04 2020-03-12 President And Fellows Of Harvard College Method for reducing parasite burden in a mosquito
BR112022022984A2 (pt) * 2020-05-11 2022-12-20 Univ Oregon Health & Science Intermediários e síntese para compostos de quinolona do tipo endoquina
WO2022144920A1 (en) * 2020-12-30 2022-07-07 Ipca Laboratories Limited Atovaquone prodrugs
WO2025151263A1 (en) * 2024-01-09 2025-07-17 Sri International Oil-based compositions and methods of making and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65715B1 (en) * 1988-08-16 1995-11-15 Wellcome Found Medicaments
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
US5021426A (en) 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
GB9207517D0 (en) 1992-04-06 1992-05-20 Wellcome Found Heterocyclic compounds
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
ITMI20070941A1 (it) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L Procedimento per la preparazione di naftochinoni trans2,3-disostituiti
EA201990064A1 (ru) * 2016-06-20 2019-05-31 Дзе Скриппс Рисерч Инститьют Противомалярийные композиции и варианты их применения

Also Published As

Publication number Publication date
AU2017281426A1 (en) 2019-01-17
KR20190020774A (ko) 2019-03-04
CA3028392A1 (en) 2017-12-28
WO2017222996A1 (en) 2017-12-28
AU2017281426B2 (en) 2021-10-14
CN109715147A (zh) 2019-05-03
JP2019523779A (ja) 2019-08-29
EP3471711A1 (en) 2019-04-24
EA201990064A1 (ru) 2019-05-31
SG10202112759SA (en) 2021-12-30
MA45411A (fr) 2019-04-24
US20190202766A1 (en) 2019-07-04
BR112018076619A2 (pt) 2019-04-02
US20210179524A1 (en) 2021-06-17
US11485697B2 (en) 2022-11-01
US10947176B2 (en) 2021-03-16
US20230111793A1 (en) 2023-04-13
EP3471711A4 (en) 2020-02-19
CN114569552A (zh) 2022-06-03

Similar Documents

Publication Publication Date Title
SG11201811434RA (en) Antimalarial compositions and uses thereof
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201910198UA (en) Multibiotic agents and methods of using the same
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201811237WA (en) Combination therapies
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809751XA (en) Egfr inhibitor compounds
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201909927RA (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
SG11201901273TA (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201908181XA (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201811351WA (en) Compositions and methods for forming stable, liquid metal oxide/hydroxide formulations
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201804587QA (en) Isoindole compounds